NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/om.
The investigation concerns whether Outset has violated federal securities laws.
Investigation Details:
On July 7, 2023, Outset disclosed that it had received a Warning Letter from the United States Food and Drug Administration ("FDA") which "assert[ed] that certain materials reviewed by the FDA and found on the Company's website promote continuous renal replacement therapy (CRRT), a modality outside of the current indications for the Tablo Hemodialysis System" and that "the TabloCart with Prefiltration . . . requires prior 510(k) clearance for marketing authorization." On this news, Outset's stock price fell $1.20, or 5.9%, to close at $19.26 per share on July 10, 2023. Then, on October 12, 2023, healthcare company Novo Nordisk announced that one of its diabetes treatments could also be used to treat chronic kidney disease. On this news, Outset Medical's stock price fell $2.05 per share, or 21.16%, to close at $7.64 per share on October 11, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchased Outset securities, you can assist this investigation by visiting the firm's site: bgandg.com/om . You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC